Delamanid for Multidrug-Resistant Pulmonary Tuberculosis
Top Cited Papers
Open Access
- 7 June 2012
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 366 (23), 2151-2160
- https://doi.org/10.1056/nejmoa1112433
Abstract
Delamanid (OPC-67683), a nitro-dihydro-imidazooxazole derivative, is a new antituberculosis medication that inhibits mycolic acid synthesis and has shown potent in vitro and in vivo activity against drug-resistant strains of Mycobacterium tuberculosis.This publication has 12 references indexed in Scilit:
- Bacteriologic monitoring of multidrug-resistant tuberculosis patients in five DOTS-Plus pilot projectsThe International Journal of Tuberculosis and Lung Disease, 2011
- Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patientsThe International Journal of Tuberculosis and Lung Disease, 2011
- Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practiceThe Lancet, 2010
- Treatment outcome of multidrug/extensively drug-resistant tuberculosis in Latvia, 2000-2004European Respiratory Journal, 2010
- Treatment Outcomes of Multidrug-Resistant Tuberculosis: A Systematic Review and Meta-AnalysisPLOS ONE, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Novel agents in the management of Mycobacterium tuberculosis disease.Current Medicinal Chemistry, 2007
- OPC-67683, a Nitro-Dihydro-Imidazooxazole Derivative with Promising Action against Tuberculosis In Vitro and In MicePLoS Medicine, 2006
- Time to Sputum Culture Conversion in Multidrug-Resistant Tuberculosis: Predictors and Relationship to Treatment OutcomeAnnals of Internal Medicine, 2006
- Community-Based Therapy for Multidrug-Resistant Tuberculosis in Lima, PeruNew England Journal of Medicine, 2003